Total submissions: 8
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Clin |
RCV005253651 | SCV005903439 | benign | RASopathy | 2024-12-03 | reviewed by expert panel | curation | The c.201A>G (p.Gln67=) variant in PPP1CB is a synonymous (silent) variant that is not predicted by SpliceAI to impact splicing. In addition, the computational predictor REVEL does not predict a damaging effect on PPP1CB function (BP4, BP7). The filtering allele frequency in gnomAD v2 is 60.64% in the European (non-Finnish) population, which is higher than the ClinGen RASopathy VCEP threshold (>0.0005) for BA1, and therefore meets this criterion (BA1). In summary, this variant meets the criteria to be classified as benign for autosomal dominant RASopathy based on the ACMG/AMP criteria applied, as specified by the ClinGen RASopathy VCEP: BA1, BP4, BP7. (RASopathy VCEP specifications version 1.3; 12/3/2024) |
Laboratory for Molecular Medicine, |
RCV000825640 | SCV000967010 | benign | not specified | 2018-03-12 | criteria provided, single submitter | clinical testing | p.Asp58Asp in exon 4 of p.Gln67Gln: This variant is not expected to have clinica l significance because it has been identified in 60.975% (77029/126328) of Europ ean chromosomes by the Genome Aggregation Database (gnomAD, http://gnomad.broadi nstitute.org; dbSNP rs1128416). ACMG/AMP Criteria applied: BA1. |
Gene |
RCV001683665 | SCV001902907 | benign | not provided | 2018-10-02 | criteria provided, single submitter | clinical testing | |
Genome- |
RCV001789369 | SCV002031811 | benign | Noonan syndrome-like disorder with loose anagen hair 2 | 2021-10-25 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV001683665 | SCV002332485 | benign | not provided | 2025-02-04 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002415953 | SCV002718478 | benign | Cardiovascular phenotype | 2018-12-04 | criteria provided, single submitter | clinical testing | This alteration is classified as benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. |
Women's Health and Genetics/Laboratory Corporation of America, |
RCV000825640 | SCV003929299 | benign | not specified | 2023-04-04 | criteria provided, single submitter | clinical testing | |
Breakthrough Genomics, |
RCV001683665 | SCV005239882 | benign | not provided | criteria provided, single submitter | not provided |